Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 21, 2026, 4:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–40 of 16 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Excess Androgen Clear all

Conditions: Polycystic Ovarian Syndrome (PCOS), Irregular Menstrual Cycles, Androgen Excess
Interventions: doxycycline, Sugar Pill; Drug · Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Polycystic Ovary Syndrome, Insulin Resistance, Insulin Sensitivity, Obesity, Pregnancy
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Hyperandrogenemia, Obesity, Polycystic Ovary Syndrome
Interventions: Hydrocortisone; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 7 Years to 18 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Polycystic Ovary Syndrome, Anovulation, Hyperandrogenism, Insulin Resistance, Glucose Intolerance, Metabolic Complication
Interventions: Placebo, Inositol; Other · Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 2
States / cities: Hershey, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Polycystic Ovary Syndrome, Healthy, Anovulation, Hyperandrogenism
Interventions: Recombinant Follicle Stimulating Hormone; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 37 Years · Female only
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Polycystic Ovary Syndrome, Anovulation, Oligoovulation, Infertility, Hyperandrogenism
Interventions: Metformin, Clomiphene citrate, Placebo; Drug
Lead sponsor: 59th Medical Wing; Federal
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2003
U.S. locations: 1
States / cities: Lackland Air Force Base, Texas

Conditions: Polycystic Ovary Syndrome, Obesity, Hyperandrogenism
Interventions: Dexamethasone, rhCG; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 7 Years to 18 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Hyperandrogenism
Interventions: Dehydroepiandrosterone (DHEA), Placebo; Dietary Supplement · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Adrenal Insufficiency, Excess Androgen, Congenital Adrenal Hyperplasia (CAH)
Interventions: Hydrocortisone (Solucortef), Insulin pump (Medtronic); Drug · Device
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Congenital Adrenal Hyperplasia (CAH), Familial Male-Limited Precocious Puberty (FMPP)
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 1 Day to 99 Years
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Polycystic Ovary Syndrome
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 2
States / cities: Research Triangle Park, North Carolina • Richmond, Virginia

Conditions: Puberty, Hyperandrogenism
Interventions: Micronized progesterone suspension, Placebo; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 10 Years to 17 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Polycystic Ovary Syndrome, Hyperandrogenism, Puberty
Interventions: Phenotype/genotype assessment; Other
Lead sponsor: University of Virginia; Other
Eligibility: 8 Years to 17 Years · Female only
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Polycystic Ovary Syndrome, Puberty Disorders, Ovulation Disorder
Interventions: Spironolactone; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 13 Years to 19 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Polycystic Ovary Syndrome (PCOS)
Interventions: Flutamide, Placebo; Drug · Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Polycystic Ovary Syndrome
Interventions: Orlistat/Meal Replacement/Lifestyle Modification, Loestrin 1/20, Combination of treatments; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 217 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 2
States / cities: Hershey, Pennsylvania • Philadelphia, Pennsylvania

Search by objective public record fields.

Effect of a Commonly Used Antibiotic, Doxycycline, in Women With Polycystic Ovarian Syndrome

Insulin Resistance Before and During Pregnancy in Women With Polycystic Ovary Syndrome

Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess

Inositol Supplementation to Treat PCOS (INSUPP-PCOS)

Ovarian Response to Recombinant Follicle Stimulating Hormone in Women With PCOS

The Effect of Metformin Added to Clomiphene Citrate on Pregnancy Rates in Hyperandrogenic, Chronic Oligoovulatory or Anovulatory Women

Ovarian Contribution to Androgen Production in Adolescent Girls

Effects of Androgen Administration on Inflammation in Normal Women

Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia

Natural History Study of Patients With Excess Androgen

Environmental Factors in the Development of Polycystic Ovary Syndrome

Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

Urinary DENND1A.V2 as a Predictor of Pubertal Hyperandrogenemia

Does Treatment of Androgen Excess Using Spironolactone Improve Ovulatory Rates in Girls With Androgen Excess?

Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women

Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women